Slides
Page 1
2025 THIRD-QUARTER RESULTS Presentation for investors, analysts and media Basel, October 29, 2025
Page 2
DISCLAIMER This presentation contains forward-looking statements, including statements regarding the beliefs, expectations and assumptions of future results, performance or achievements of Straumann Group, that are based upon information available to Straumann Group as of the date such statements are made. Forward-looking statements are neither historical facts nor assurances of future performance. They may, but need not, be identified by words such as: "anticipate," "intend," "plan," "goal," "believe," "project," "estimate," "expect," "future," "likely," "may," "should," "will" and similar references to future periods or events. Such forward-looking statements reflect the views, beliefs, assumptions and expectationsof Straumann Group or its management at the time the statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may be outside of Straumann Group’s control. Such known and unknown risks, uncertainties and other factors underlying forward-looking statements may cause the actual results, performance or achievements of the Group to differ materially from those expressed or implied in this presentation. Accordingly, you should not rely on any forward-looking statements contained in this presentation. Important factors that could cause the Group’s expectations regarding future results, performance or achievements to differ materially from those expressed in a forward- looking statement include, but are not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann Group's control. Should one or more of these risks, uncertainties or other factors materialize or should underlying views, beliefs, assumptions or expectations prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann Group is providing the information in this presentation as of the date it is given and does not undertake any obligation to update any statements as a result of new information, future events or otherwise. This presentation constitutes neither an offer to sell nor a solicitation to buy any securities. 2
Page 3
Highlights Guillaume Daniellot Financials Isabelle Adelt Recent achievements & strategy Guillaume Daniellot Outlook 2025 Guillaume Daniellot Q&A Guillaume Daniellot, Isabelle Adelt AGENDA 3
Page 4
HIGHLIGHTS Guillaume Daniellot, CEO 4
Page 5
STRONG 8.3 % ORGANIC GROWTH AND OUTLOOK CONFIRMED 1 Financials refer to continuous operations 2 Organic growth excluding FX and M&A effects5 China Campus inaugurated and in full production Strengthening supply chain resilience ahead of VBP 2.0 in China Organic revenue growth 1, 2 8.3% Nine-month: 9.6% 1, 2 Outlook 2025 confirmed3 High-single digit organic revenue growth with 30 to 60 basis points improvement of the core EBIT margin at constant 2024 currency rates Orthodontics transformation Smartee global partnership Additional partnership with DentalMonitoring Third-quarter revenue in 2025 1 602.0 m Nine-month: 2.0 billion 1 3 Barring unforeseen events Innovation New SIRIOS X3 New intraoral scanner integrated into AXS
Page 6
EMEA Q3 11.2% Q3 24 11.4% NAM Q3 5.7% Q3 24 2.0% LATAM Q3 18.0% Q3 24 18.9% APAC Q3 3.2% Q3 24 19.7% STRONG PERFORMANCE – REGIONAL DIFFERENCES REMAIN * % of Q3 2025 Group total revenue6 10 %* GROUP 27 %* 39 %* 24 %* Organic revenue growth in the third quarter
Page 7
FINANCIALS Isabelle Adelt, CFO 7
Page 8
8 Regional % share of organic growth 23 9 4 10 Revenue Q3 2024 -30 FX effect Revenue Q3 2025 LATAM 586 556 APACNAMEMEA 0 Adjusted Revenue base M&A effect 602 +8.3% Organic +2.9% Change in organic growth +5.7% +18.0%+11.2% +3.2% 51 20 19 10 Q3 2025 APAC LATAM EMEA NAM STRONG RESULTS WITH CONSIDERABLE FX HEADWINDS Revenue development breakdown in CHF million, rounded
Page 9
TARIFFS MITIGATION EFFORTS 9 Inventory build-up and supply flexibility ▪ Stock increases in key markets to secure continuity ▪ Adjusted logistics flows to mitigate near-term cost impact 2025 Local production and supply chain optimization ▪ Increased share of locally produced finished products ▪ Local assembly and packaging line implemented to reduce tariff exposure and improve supply efficiency 2026 Actively implemented mitigation measures to counter the effects of tariffs
Page 10
REINVESTING WHERE RETURN ON CAPITAL IS HIGHEST 10 Capital allocation priority order Reinvest in sustainable business growth Maintain strong balance sheet Pursue M&A to accelerate strategy Maintain and increase dividend with earnings growth 3 2 1 4
Page 11
STRATEGIC HIGHLIGHTS Guillaume Daniellot, CEO 11
Page 12
HUGE OPPORTUNITIES – IMPLANTOLOGY & BEYOND Source: Straumann Group estimates12 Addressable market of about CHF 20bn globally Market share % Market size in CHF bn 35% Implantology Regeneratives ClearAligner CADCAM equipment CADCAM prosthetics 6.0 0.7 4.7 2.6 5.6 ~3%~15% 35% >5% <5% MARKET SHARE GROWTH THROUGH INNOVATION Straumann Group share within the addressable market in 202412.5%
Page 13
TRANSFORM OUR ORTHO BUSINESS FOR COMPETITIVENESS 13 • Smartee is a leading clear aligner company and innovation partner with strong presence in Asia • Accelerates our value proposition covering broader coverage of indications • Improves manufacturing efficiency and cost structure through fully automated production New partnership with Smartee to strengthen value proposition and profitability
Page 14
TRANSFORMING CLEARCORRECT’S VALUE PROPOSITION 14 AI monitoring expanding GP adoption Advances software & new clinical features Powered by DentalMonitoring and seamlessly integrated into the ClearCorrect Doctor Portal. New treatment outcome simulation and mandibular advancement.
Page 15
Market share % Market size in CHF bn 35% 35% STRAUMANN INNOVATION DRIVING PREMIUM IMPLANTOLOGY 15 Implantologie 6.0 % 35% Implantology BLC TLC BLX TLX
Page 16
EDUCATION AS A KEY DRIVER TO CAPTURE MARKET SHARE 16 EAO, Esthetic Days and DSO CEO Summit
Page 17
LAUNCH OF NEW X3 INTRAORAL SCANNER 17 SIRIOS X3 Mid Entry Premium TRIOS 5/6 SIRIOS SIRIOS X3 • • •
Page 18
Full-Arch: Straumann EXACT digital impression solution 18 DRIVING EFFICIENCY THROUGH NEWLY LAUNCHED DIGITAL WORKFLOWS Single tooth: Straumann Fast Molar solution
Page 19
STRENGTHENING OUR POSITION IN CHINA AHEAD OF VBP 2.0 19 ▪ Shanghai campus ramp-up completed; first local production ▪ Local manufacturing driving efficiency ▪ Multi-brand strategy expanding market access including new local eco-brand developed in partnership ▪ Offering education programs to advance implantology skills in China
Page 20
EMPOWERING SMILES THROUGH OUR CULTURE OF CARE 20 Smile Movement 5 000+ employees united for a cause
Page 21
OUTLOOK Guillaume Daniellot, CEO 21
Page 22
CONFIRMED OUTLOOK 2025 22 Barring unforeseen circumstances Market environment and assumption • Uncertain economic environment remains • Group believes global patient flow should remain stable • Continue to outgrow market Revenue and profitability • Organic revenue growth in the high single-digit percentage range • With 30 to 60 basis points improvement of the core EBIT margin at constant 2024 currency rates
Page 23
23 CAPITAL MARKETS DAY 2025 SWITZERLAND 24 NOVEMBER SITE VISIT IN VILLERET 25 NOVEMBER CAPITAL MARKETS DAY IN BASEL
Page 24
THANK YOU YOUR QUESTIONS? 24
Page 25
CALENDAR OF UPCOMING EVENTS 25 2025 Event Location 4 – 5 November J.P . Morgan UK Roadshow London 5 November ZKB Swiss Equity Conference Zurich 6 November ODDO Germany Roadshow Frankfurt 25 November Capital Markets Day Basel & Webcast 2 December Citi Global HC Conference Miami 3 December Evercore HC Conference Miami 1 Jan – 17 Feb 2026 Quiet period 18 February 2026 Full-Year 2025 Results Webcast